Eccrine Squamous Syringometaplasia Secondary to Pegylated Liposomal Doxorubicin

Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: Reappraisal of epidemiological, clinical, and pathological features

“…[1][2][3][4] It has been described in association with multiple well-defined entities as an incidental finding, and it is particularly seen in patients receiving chemotherapy for various malignant neoplasms (Table I). 5 In 1997 and 1996, Valks et al 6 and Prussick 7 respectively suggested the existence of a characteristic clinical pattern exclusively affecting the intertriginous areas, together with the presence of ESS as the main histologic feature. This pattern appeared specifically as a drug reaction secondary to cytostatic agents.…”

Olanzapine-Induced Eccrine Squamous Syringometaplasia

“…21,22 ESS has not been reported in association with antipsychotic drugs. It is not known whether olanzapine is secreted in sweat; however, interaction of olanzapine with adrenergic receptors is known to have an influence on the autonomic regulation of sweat glands and blood vessels in the skin 23 ; thus, the 24 idiopathic *Secondary to tissue ischemia or as a manifestation of regeneration after necrosis possibility exists that in our patient, anticholinergic effects of olanzapine were causally involved in the development of ESS.…”

Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition

“…TEC is most commonly associated with anthracyclines, cytarabine, and other antimetabolites 1 . Interestingly, however, similar eruptions may also occur with tyrosine kinase inhibitors, despite their lack of cytotoxicity 1, 4, 5, 6. The cohort in this case series is too small and their treatments too varied to determine additional correlations among types of chemotherapy or malignancy and the subsequent rash.…”

“…The presumed pathophysiology of TEC is excretion of cytotoxic agents into eccrine sweat ducts, yielding localized toxic effects 1, 2, 4. Areas with high concentrations of eccrine ducts and those vulnerable to sweat trapping are at increased risk.…”